Tianjin Medical University Cancer Institute and Hospital: Lung Neoplasms trials

The registry lists 45 Lung Neoplasms studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 16 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 28Phase 3 4Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07244926Phase 2
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid TumorsRecruitingNCT07058948Phase 2
• Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLCRecruitingNCT06939127Phase 2
• Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction TherapyNot yet recruitingNCT06914050Phase 2
• Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung CancerRecruitingNCT06775678Phase 2
• Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation ProceduresNot yet recruitingNCT06581107Not applicable
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2
• A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk FactorsNot yet recruitingNCT06143735Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung CancerRecruitingNCT05975944Phase 1/2
• Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
• PD1 and PARP for Maintenance Therapy in NSLLCRecruitingNCT05392686Phase 2
• Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
• Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLCRecruitingNCT04631770Not applicable
• Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCRecruitingNCT04530227Phase 2
• Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingNCT03992885Phase 3
• Single-center, Prospective Study on the Identification and Delineation of Brain and Lung Tumors and At-Risk Organs, and Functional Testing of Surrounding Tissues Based on Dual-Energy CTStatus unknownNCT06301100
• Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous CarcinomaStatus unknownNCT05854030
• Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at RiskCompletedNCT05787522
• Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2
• Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
• Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung CancerStatus unknownNCT04882033Phase 1
• Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung CancerActive, not recruitingNCT04836728Phase 2
• Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
• Almonertinib With Chemotherapy in mEGFR NSCLCStatus unknownNCT04646824Phase 2
• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLCStatus unknownNCT04193098Phase 1
• Appatinib Combined With S-1 in the Treatment of Small Cell Lung CancerStatus unknownNCT04128800Phase 2
• Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion MutationStatus unknownNCT04063462Phase 2
• Methods of Computed Tomography Screening and Management of Lung CancerStatus unknownNCT03992833Not applicable
• Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLCStatus unknownNCT03987867Phase 1
• Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung CancerStatus unknownNCT03944980Phase 3
• Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC PatientsStatus unknownNCT03874000Phase 2
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
• PERCIST Criteria for Response Evaluation With Solid TumorsStatus unknownNCT02765620
• Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLCCompletedNCT02497118Phase 4
• Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)Status unknownNCT01745445Phase 2
• Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFRStatus unknownNCT01744925Phase 2
• Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as ChemotherapyStatus unknownNCT01660399Phase 2
• Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung CancerCompletedNCT01631357Phase 2/3
• Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC PatientsStatus unknownNCT01393080Not applicable
• GWAS Research of Lung Cancer in TianjinStatus unknownNCT01255059
• Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)CompletedNCT01099124Not applicable
• Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)SuspendedNCT00986284Phase 2
• Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung CancerStatus unknownNCT00973310Phase 2